Avodart (dutasteride) capsules 0.5 mg. №90

Avodart (dutasteride) capsules 0.5 mg. №90

$214.00

Manufacturer: Poland

Avodart (dutasteride) is used for the treatment of symptoms of benign prostatic hyperplasia, also for reducing the risk of acute urinary retention.

Category:

Description

Ingredients

active ingredient: dutasteride;

1 capsule contains dutasteride 0.5 mg;

excipients: caprylic / capric acid monodiglycerides, butylhydroxytoluene (E 321);

capsule shell: gelatin, glycerin, titanium dioxide (E 171), iron oxide yellow (E 172), medium chain triglycerides and lecithin.

Dosage form

Soft gelatin capsules.

Basic physical and chemical properties: pale yellow opaque oblong soft gelatin capsules marked GX CE2.

Pharmacotherapeutic group

Drugs used in benign prostatic hyperplasia. Testosterone-5a-reductase inhibitors. Code ATX G04C B02.

Pharmacodynamics

Dutasteride is a dual 5a-reductase inhibitor that inhibits both type 1 and type 2 5a-reductase isoenzymes responsible for the conversion of testosterone to 5a-dihydrotestosterone. Dihydrotestosterone is an androgen that is primarily responsible for hyperplasia of the prostate tissue. The maximum decrease in dihydrotestosterone while taking Avodart depends on the dose and is observed in the first 1-2 weeks. After the 1st and 2nd weeks of using Avodart at a daily dose of 0.5 mg, the average concentration of dihydrotestosterone decreases by 85 and 90%, respectively.

In patients with benign prostatic hyperplasia who received 0.5 mg dutasteride per day, the average decrease in dihydrotestosterone levels was 94% after 1 year and 93% after 2 years of treatment, the average testosterone level increased by 19% after 1 and 2 years.

Indications

Treatment of symptoms of moderate and severe benign prostatic hyperplasia; reducing the risk of acute urinary retention and the need for surgical intervention in patients with symptoms of moderate and severe benign prostatic hyperplasia.

Contraindications

Avodart is contraindicated in patients with hypersensitivity to dutasteride, other 5a-reductase inhibitors, soy, peanuts or other components of the drug.

Avodart is not used to treat women and children (see Use during pregnancy and lactation).

Avodart is contraindicated in patients with severe hepatic impairment.

Dosage and administration

Avodart can be given as monotherapy or in combination with the alpha-blocker tamsulosin (0.4 mg).

Adult men (including elderly patients)

The recommended dose of Avodart is 1 capsule (0.5 mg) per day orally. The capsule should be swallowed whole, not opened or chewed, as contact with the contents of the capsule may irritate the oral and pharyngeal mucosa.

Avodart can be taken with or without food.

Despite the fact that relief from taking the drug can be observed at an early stage, for an objective assessment of the effectiveness of treatment, it should be continued for at least 6 months.

kidney failure

The pharmacokinetics of dutasteride in patients with renal insufficiency has not been studied, therefore, patients with severe renal insufficiency should be prescribed with caution.

Liver failure

The pharmacokinetics of dutasteride in patients with hepatic insufficiency has not been studied, therefore, caution should be used in mild to moderate hepatic insufficiency. The drug is contraindicated in patients with severe hepatic insufficiency.

Related products